Verition Fund Management
IBRX icon

Verition Fund Management’s ImmunityBio IBRX Stock Holding History

Verition Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Buy
382,600
+13,200
+4% +$99.9K 0.02% 857
2026
Q1 		$2.83M Buy
+369,400
New +$2.53M 0.02% 843

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management's IBRX Position: Q2 2026 in Review

Verition Fund Management opened a new position in ImmunityBio (IBRX) in Q2 2026: 28,280 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #1796 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in IBRX as recently as Q4 2025.

Verition Fund Management first reported a position in IBRX in Q1 2023 and has held it in 10 quarters since. The position peaked at $2.49M in Q1 2025. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Verition Fund Management held 28,280 shares of ImmunityBio worth $248K as of Q2 2026.
  • ImmunityBio was a new Verition Fund Management position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1796 holding.
  • Verition Fund Management first reported a position in ImmunityBio in Q1 2023 and has held it in 10 quarters since.
  • Verition Fund Management's ImmunityBio position peaked at $2.49M in Q1 2025.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.